Browse the corpus

Denosumab, a bone anti-resorptive medication, treats osteoporosis and various bone-related disorders. Its FDA-approved applications span a spectrum of conditions, encompassing the prevention of skeletal-related events such as bone pain and fractures arising secondary to multiple myeloma or bone metastases from solid tumors, giant cell tumors of the bone, hypercalcemia of malignancy, osteoporosis in postmenopausal women at high fracture risk, and men facing an increased risk of fracture due to osteoporosis or glucocorticoid-induced bone loss. This activity focuses on elucidating denosumab's mechanism of action, adverse event profile, toxicity considerations, optimal dosing strategies, pharmacodynamics, and the essential parameters for diligent monitoring. Interprofessional team members will increase their understanding of when denosumab therapy is indicated, thereby facilitating optimal patient outcomes. Participants gain comprehension of denosumab's pivotal role as a total human IgG2 monoclonal antibody. By selectively binding to the receptor activator of the NF kappa B ligand (RANKL), denosumab competently inhibits its interaction with the NF kappa B receptor activator (RANK). This inhibition forms the crux of its therapeutic efficacy in preventing bone resorption and mitigating associated risks. The content strategically navigates through pertinent aspects, empowering healthcare professionals to make informed decisions and contribute effectively to patient care within denosumab therapy. Objectives: Identify the appropriate indications for denosumab therapy in treating osteoporosis, metastatic bone disease, certain bone tumors, and treatment-induced bone loss. Screen patients for eligibility and assess their suitability for denosumab therapy, considering factors such as medical history, concurrent medications, and potential contraindications. Apply knowledge of the adverse effects of denosumab and proactively manage and monitor potential complications. Implement effective communication with patients about denosumab therapy's benefits, risks, and expectations, ensuring informed and shared decision-making. Access free multiple choice questions on this topic.

Atypical Bone Fractures: Although the incidence remains low, prolonged bisphosphonate therapy is associated with atypical bone fractures. However, clinicians have also observed these fractures in those receiving denosumab for osteoporosis or metastatic bone disease. These fractures usually occur in the subtrochanteric region or along the femur shaft. Patients tend to feel prodromal pain from weeks to months leading up to the fracture. Fractures commonly occur with little to no trauma in the area. Experts are currently unsure if the atypical fractures occur secondary to denosumab toxicity or the patient’s underlying osteoporosis. Patients should receive counseling regarding the potential for new hip or thigh pain, and the contralateral limb should be examined if an atypical fracture is suspected. Upon diagnosis of an atypical fracture, possible discontinuation of denosumab is an option. Consider initiating a different osteoporosis therapy if discontinuing denosumab due to increased fracture risk.[30] Hypersensitivity: Reports exist of clinically severe anaphylactic reactions. Symptoms may include rash, pruritus, urticaria, facial edema, airway edema, and possibly hypotension. If these symptoms occur, initiate appropriate treatment and subsequently discontinue denosumab. Hypocalcemia: Due to its anti-resorptive effects, denosumab can potentially cause hypocalcemia. There is documentation of severe, even fatal, cases of denosumab-induced hypocalcemia. Those with severe renal dysfunction may have an increased risk of developing hypocalcemia. Clinicians should obtain serum calcium and correct preexisting hypocalcemia at the initiation of treatment. In patients with preexisting hypocalcemia, serum calcium requires frequent monitoring. Use denosumab with caution in those who have predisposing conditions to hypocalcemia.[31] Osteonecrosis of the Jaw (ONJ): Reports of ONJ have been observed in those receiving denosumab. Symptoms may include jaw pain, tooth infection, bone, gingival erosion, and toothache. An increased risk of being diagnosed with ONJ correlates directly to the duration of denosumab exposure. Those with predisposing factors, such as poor dentition and recent tooth extraction, have a higher risk.

Osteonecrosis of the Jaw (ONJ): Reports of ONJ have been observed in those receiving denosumab. Symptoms may include jaw pain, tooth infection, bone, gingival erosion, and toothache. An increased risk of being diagnosed with ONJ correlates directly to the duration of denosumab exposure. Those with predisposing factors, such as poor dentition and recent tooth extraction, have a higher risk. If osteonecrosis of the jaw is suspected, make arrangements for a thorough dental exam. The risk of ONJ is considerably higher in patients with malignancy receiving denosumab than in patients with osteoporosis receiving denosumab. Denosumab should not be initiated until dental health is optimized. While on denosumab for cancer therapy, dental procedures are contraindicated. If ONJ is suspected, discontinue denosumab.[19] Dermatologic Reactions: Reports of dermatitis, eczema, and rash have been observed. If symptoms are severe, consider discontinuation of denosumab.[21]

Clinicians who prescribe denosumab should monitor for adverse drug reactions. The patient should receive a baseline evaluation from a dentist before initiating treatment. Endocrinologists and gynecologists play an essential role in treating patients with postmenopausal osteoporosis receiving denosumab. The role of oncologists is crucial in treating patients receiving denosumab for multiple myeloma or giant cell tumors. Nurses should educate the patients and monitor their compliance. Pharmacists should perform thorough medication reconciliation and ensure antiresorptive treatment is started after stopping denosumab. Pharmacists should alert the prescriber in case of potential adverse drug reactions or deviation from the treatment plan. The patient's electrolytes and renal function also require monitoring at regular intervals. In case of severe hypocalcemia, emergency medicine clinicians should rapidly stabilize the patient. The most severe complication of therapy is osteonecrosis of the jaw; an oral exam is necessary at each visit. Periodic bone density evaluation every 1 to 2 years is the recommended interval for follow-up. Interprofessional teamwork between clinicians, specialists, pharmacists, and dentists can maximize therapeutic efficacy, decrease the incidence of preventable adverse drug reactions, and optimize the treatment outcomes related to denosumab therapy.